Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
LONDON, UK / ACCESSWIRE / April 19, 2023 / Tiziana Life Sciences (NASDAQ:TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is...
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise
LONDON, UK / ACCESSWIRE / April 17, 2023 / Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through...